Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy
Background and aimsHCV genotype (GT) 3 is associated with rapid liver disease progression. However, the liver disease progression and its risk factors in patients with HCV GT 3 infection after sustained virological response (SVR) following direct-acting antivirals (DAAs) remain unclear. Therefore, w...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1510939/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548279138648064 |
|---|---|
| author | Xiping Ran Xiping Ran Yang Xu Ying Wang Cheng Zeng Chen Gong Ni Wang Dachuan Cai Dachuan Cai |
| author_facet | Xiping Ran Xiping Ran Yang Xu Ying Wang Cheng Zeng Chen Gong Ni Wang Dachuan Cai Dachuan Cai |
| author_sort | Xiping Ran |
| collection | DOAJ |
| description | Background and aimsHCV genotype (GT) 3 is associated with rapid liver disease progression. However, the liver disease progression and its risk factors in patients with HCV GT 3 infection after sustained virological response (SVR) following direct-acting antivirals (DAAs) remain unclear. Therefore, we aimed to investigate the liver disease progression of patients with GT 3 after SVR.MethodsThis was a retrospective cohort study of patients with HCV infection who achieved SVR by DAAs. The clinical outcome was overall liver disease progression (OLDP), defined as newly diagnosed compensated liver cirrhosis, decompensated liver cirrhosis, or hepatocellular carcinoma. The incidence of OLDP was evaluated by Kaplan−Meier analysis. Cox regression analysis identified the risk factors for OLDP.ResultsA total of 409 patients (46.9% GT3) were followed for 43.7 (32.9, 58.7) months. The incidence of OLDP was higher in patients with GT 3 (4.63/100PY) than non-GT 3 (0.60/100PY; P < 0.001). According to Cox multivariate analysis, GT 3 was significantly associated with OLDP (HR 6.41, 95% CI 1.82 - 22.56; P=0.004). The predictors of OLDP in patients with GT 3 were HCV recurrence (HR 12.15, 95% CI 3.18 - 46.46; P < 0.001) and FIB-4 > 3.25 (HR 16.40, 95% CI 1.03 - 39.81; P = 0.046) at baseline.ConclusionHCV GT 3-infected patients remain at a higher risk of OLDP even after achieving SVR by DAAs, especially patients with advanced liver fibrosis and at high risk for reinfection or virological late relapse. |
| format | Article |
| id | doaj-art-93b5368d40a44977b108ca4782de5519 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-93b5368d40a44977b108ca4782de55192025-02-03T06:33:41ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-02-011510.3389/fcimb.2025.15109391510939Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapyXiping Ran0Xiping Ran1Yang Xu2Ying Wang3Cheng Zeng4Chen Gong5Ni Wang6Dachuan Cai7Dachuan Cai8Department of Gastroenterology, Chonggang General Hospital, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaDepartment of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, ChinaBackground and aimsHCV genotype (GT) 3 is associated with rapid liver disease progression. However, the liver disease progression and its risk factors in patients with HCV GT 3 infection after sustained virological response (SVR) following direct-acting antivirals (DAAs) remain unclear. Therefore, we aimed to investigate the liver disease progression of patients with GT 3 after SVR.MethodsThis was a retrospective cohort study of patients with HCV infection who achieved SVR by DAAs. The clinical outcome was overall liver disease progression (OLDP), defined as newly diagnosed compensated liver cirrhosis, decompensated liver cirrhosis, or hepatocellular carcinoma. The incidence of OLDP was evaluated by Kaplan−Meier analysis. Cox regression analysis identified the risk factors for OLDP.ResultsA total of 409 patients (46.9% GT3) were followed for 43.7 (32.9, 58.7) months. The incidence of OLDP was higher in patients with GT 3 (4.63/100PY) than non-GT 3 (0.60/100PY; P < 0.001). According to Cox multivariate analysis, GT 3 was significantly associated with OLDP (HR 6.41, 95% CI 1.82 - 22.56; P=0.004). The predictors of OLDP in patients with GT 3 were HCV recurrence (HR 12.15, 95% CI 3.18 - 46.46; P < 0.001) and FIB-4 > 3.25 (HR 16.40, 95% CI 1.03 - 39.81; P = 0.046) at baseline.ConclusionHCV GT 3-infected patients remain at a higher risk of OLDP even after achieving SVR by DAAs, especially patients with advanced liver fibrosis and at high risk for reinfection or virological late relapse.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1510939/fullhepatitis C virusdirect-acting antiviralsustained virological responseHCV genotype 3disease progression |
| spellingShingle | Xiping Ran Xiping Ran Yang Xu Ying Wang Cheng Zeng Chen Gong Ni Wang Dachuan Cai Dachuan Cai Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy Frontiers in Cellular and Infection Microbiology hepatitis C virus direct-acting antiviral sustained virological response HCV genotype 3 disease progression |
| title | Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy |
| title_full | Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy |
| title_fullStr | Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy |
| title_full_unstemmed | Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy |
| title_short | Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy |
| title_sort | genotype 3 is linked to worse liver disease progression in hepatitis c patients even after svr following daa therapy |
| topic | hepatitis C virus direct-acting antiviral sustained virological response HCV genotype 3 disease progression |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1510939/full |
| work_keys_str_mv | AT xipingran genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT xipingran genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT yangxu genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT yingwang genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT chengzeng genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT chengong genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT niwang genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT dachuancai genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy AT dachuancai genotype3islinkedtoworseliverdiseaseprogressioninhepatitiscpatientsevenaftersvrfollowingdaatherapy |